Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 08:04   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

3082  4010  543  425 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 197.72-0.93 
 IWM 113.60-1.04 
 FB 75.19+0.21 
 SIRI 3.44-0.01 
 AAPL 97.671+0.641 
 EEM 44.78-0.18 
 XLF 22.895-0.125 
 GDX 26.82+0.74 
 BAC 15.59-0.03 
 F 17.62-0.22 
Partners & Brokers